Respirology (Carlton, Vic.) · 2025
Validation and Further Analysis of the COPD Exacerbation Recognition Tool (CERT).
СтатьяВалидационное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xing Xiangju, Liu Xiang, Jones Paul W, Liao Xiuqing, Ma Qianli, Huang Lili, Wei Xiaoling, Luo Chengling, Zhao Yumei, Wang Li, Lu Ling, Zhang Ju, Chen Min, Liao Banghong, Wang Changzheng, Yao Wei
Аннотация
BACKGROUND AND OBJECTIVE: The COPD Exacerbation Recognition Tool (CERT) contains five symptoms that may change at the onset of an exacerbation. It was designed to help patients with COPD recognise the onset of an exacerbation and seek medical attention. This study tested its sensitivity and specificity and further examined its properties.
METHODS: Stable and exacerbating patients presenting to three tertiary hospitals in China were enrolled. Patients' responses to the CERT were compared with physicians' diagnoses made using GOLD 2021 criteria. The CERT was assessed as recommended, and as a total score, using scores assigned to the degree of change for each of the five symptoms (total score 15). Exploratory factor analysis (EFA) was used to identify the key components of the CERT and potentially reduce the number of items.
RESULTS: Sensitivity and specificity of the original CERT were 92.4% and 72.1%. Using a cut-off value of 6, the score-based CERT had the better sensitivity (94.3%) and specificity (86.9%). Concordance between CERT and physician diagnosis was higher with the scored version (kappa 0.833) versus the original version (kappa 0.666). Using EFA, two components were identified 'cough and sputum' and 'breathlessness and activity limitation' with a cumulative variance of 82.3%.
CONCLUSION: The original and scored-based CERT both had good sensitivity and specificity, but the score-based version showed better concordance with physician diagnosis. The use of two representative items in a 2-item scored version was also effective in identifying acute exacerbations.
TRIAL REGISTRATION: ChiCTR2400090589 registered with https://www.chictr.org.cn.
METHODS: Stable and exacerbating patients presenting to three tertiary hospitals in China were enrolled. Patients' responses to the CERT were compared with physicians' diagnoses made using GOLD 2021 criteria. The CERT was assessed as recommended, and as a total score, using scores assigned to the degree of change for each of the five symptoms (total score 15). Exploratory factor analysis (EFA) was used to identify the key components of the CERT and potentially reduce the number of items.
RESULTS: Sensitivity and specificity of the original CERT were 92.4% and 72.1%. Using a cut-off value of 6, the score-based CERT had the better sensitivity (94.3%) and specificity (86.9%). Concordance between CERT and physician diagnosis was higher with the scored version (kappa 0.833) versus the original version (kappa 0.666). Using EFA, two components were identified 'cough and sputum' and 'breathlessness and activity limitation' with a cumulative variance of 82.3%.
CONCLUSION: The original and scored-based CERT both had good sensitivity and specificity, but the score-based version showed better concordance with physician diagnosis. The use of two representative items in a 2-item scored version was also effective in identifying acute exacerbations.
TRIAL REGISTRATION: ChiCTR2400090589 registered with https://www.chictr.org.cn.